Juan Garcia Burgos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Juan Garcia Burgos has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Steffen Thirstrup
European Medicines Agency, Amsterdam, The Netherlands
5 shared publications - Bruno Sepodes
Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal
3 shared publications - Claudio Costantino
Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties “G. D’Alessandro”—Hygiene Section, University of Palermo , Palermo
3 shared publications - Indiana Castro
Public and Stakeholder Engagement Department, European Medicines Agency, Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
3 shared publications - Marie Van Tricht
Public and Stakeholder Engagement Department, European Medicines Agency, Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
3 shared publications - Martina Sciortino
Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE) “G. D’Alessandro”, University of Palermo, 90127 Palermo, Italy
3 shared publications
Latest Publications
- 8 January 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 61
European Medicines Agency approvals of new medicines in November and December 2025
- 8 January 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 61
European Medicines Agency approvals of new medicines in November and December 2025
- 5 November 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (12) , 3301-3303
European Medicines Agency seeks stakeholders' views on its reflection paper on patient experience data
- 5 November 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (12) , 3301-3303
European Medicines Agency seeks stakeholders' views on its reflection paper on patient experience data
- Open Access
Correction: Castro et al. Stakeholders’ Understanding of European Medicine Agency’s COVID-19 Vaccine Information Materials in EU and Regional Contexts. Vaccines 2023, 11, 1616
The author would like to make the following correction to this publication
Open AccessCorrection: Castro et al. Stakeholders’ Understanding of European Medicine Agency’s COVID-19 Vaccine Information Materials in EU and Regional Contexts. Vaccines 2023, 11, 1616
The author would like to make the following correction to this publication
- 25 September 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 57
European medicines agency approvals of new medicines in July and August 2025
- 25 September 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 57
European medicines agency approvals of new medicines in July and August 2025
- Open Access
- 21 May 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 53, 101331
The European Medicines Agency and The Lancet Regional Health—Europe join forces to protect public health
- 21 May 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 53, 101331
Open AccessThe European Medicines Agency and The Lancet Regional Health—Europe join forces to protect public health
- 20 May 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 54
European Medicines Agency approvals of new medicines in March and April 2025
- 20 May 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 54
European Medicines Agency approvals of new medicines in March and April 2025
- 1 April 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 51, 101279
EMA approvals of new medicinal products and new biosimilar products in January and February 2025
- 1 April 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 51, 101279
EMA approvals of new medicinal products and new biosimilar products in January and February 2025
- Open Access
Stakeholders’ Understanding of European Medicine Agency’s COVID-19 Vaccine Information Materials in EU and Regional Contexts
The COVID-19 pandemic posed challenges to communicating accurate information about vaccines because of the spread of misinformation. The European Medicines Agency (EMA) tried to reassure the public by communicating early on about the development and approval of COVID-19 vaccines. The EMA surveyed patients/consumers, healthcare professional organizations, and individual stakeholders, both at the EU level and in an Italian regional context. The objectives of the study were to see if the EMA’s core information materials were informative and well-understood and which communication channels were preferred by the public. The main findings showed that individual patients/consumers generally prefer to obtain information about COVID-19 vaccines from the internet or mass media, while organizations and individual healthcare professionals prefer to obtain information from national and international health authorities. Both at EU and local levels, participants had a good understanding of the key messages from regulators and found the materials useful and relevant. However, some improvements were recommended to the visual, text, and dissemination formats, including publishing more information on safety and using a more public-friendly language. Also, it was recommended to maintain the EMA’s approach of using media, stakeholder engagement, and web-based formats to communicate about COVID-19 vaccines. In conclusion, user-testing of proactive communication materials aimed to prebunk misinformation during a public health crisis helps to ensure that users understand the development and safety of novel vaccine technologies. This information can then be used as a basis for further evidence-based communication activities by regulators and public health bodies in an emergency context.
Open AccessStakeholders’ Understanding of European Medicine Agency’s COVID-19 Vaccine Information Materials in EU and Regional Contexts
The COVID-19 pandemic posed challenges to communicating accurate information about vaccines because of the spread of misinformation. The European Medicines Agency (EMA) tried to reassure the public by communicating early on about the development and approval of COVID-19 vaccines. The EMA surveyed patients/consumers, healthcare professional organizations, and individual stakeholders, both at the EU level and in an Italian regional context. The objectives of the study were to see if the EMA’s core information materials were informative and well-understood and which communication channels were preferred by the public. The main findings showed that individual patients/consumers generally prefer to obtain information about COVID-19 vaccines from the internet or mass media, while organizations and individual healthcare professionals prefer to obtain information from national and international health authorities. Both at EU and local levels, participants had a good understanding of the key messages from regulators and found the materials useful and relevant. However, some improvements were recommended to the visual, text, and dissemination formats, including publishing more information on safety and using a more public-friendly language. Also, it was recommended to maintain the EMA’s approach of using media, stakeholder engagement, and web-based formats to communicate about COVID-19 vaccines. In conclusion, user-testing of proactive communication materials aimed to prebunk misinformation during a public health crisis helps to ensure that users understand the development and safety of novel vaccine technologies. This information can then be used as a basis for further evidence-based communication activities by regulators and public health bodies in an emergency context.
- Open Access
- 14 August 2023
- Published by MDPI AG in Preprints.org
Analysis of European Medicines Agency’s COVID-19 Vaccine Information Materials in EU and Regional Context
The COVID-19 pandemic made it harder to communicate accurate information about vaccines because of the spread of misinformation. The European Medicines Agency (EMA) tried to reas-sure the public by communicating about the development and approval of COVID-19 vaccines. They surveyed patients/consumers, healthcare professional organizations, and individual stake-holders to see if their core information materials were informative and well understood. They also asked about the public's preferred communication channels. The surveys showed that indi-vidual patients/consumers generally prefer to get information about COVID-19 vaccines from the internet or mass media. Organizations and individual healthcare professionals prefer to get in-formation from national and international health authorities' sources. This supports EMA's ap-proach of using media, stakeholder engagement, and web-based formats to communicate about COVID-19 vaccines. Both at the EU and local levels, participants had a good understanding of the key messages from regulators and found the materials useful and relevant. However, some im-provements were recommended to the visuals, texts, and dissemination formats. These recom-mendations were generally consistent in both contexts. User-testing of proactive communication materials aimed at prebunking misinformation during a public health crisis helps to ensure that users understand the development and safety safeguards of novel vaccine technologies. This in-formation can then be used as a basis for evidence-based communication activities by regulators and public health bodies in an emergency context.
- 14 August 2023
- Published by MDPI AG in Preprints.org
Open AccessAnalysis of European Medicines Agency’s COVID-19 Vaccine Information Materials in EU and Regional Context
The COVID-19 pandemic made it harder to communicate accurate information about vaccines because of the spread of misinformation. The European Medicines Agency (EMA) tried to reas-sure the public by communicating about the development and approval of COVID-19 vaccines. They surveyed patients/consumers, healthcare professional organizations, and individual stake-holders to see if their core information materials were informative and well understood. They also asked about the public's preferred communication channels. The surveys showed that indi-vidual patients/consumers generally prefer to get information about COVID-19 vaccines from the internet or mass media. Organizations and individual healthcare professionals prefer to get in-formation from national and international health authorities' sources. This supports EMA's ap-proach of using media, stakeholder engagement, and web-based formats to communicate about COVID-19 vaccines. Both at the EU and local levels, participants had a good understanding of the key messages from regulators and found the materials useful and relevant. However, some im-provements were recommended to the visuals, texts, and dissemination formats. These recom-mendations were generally consistent in both contexts. User-testing of proactive communication materials aimed at prebunking misinformation during a public health crisis helps to ensure that users understand the development and safety safeguards of novel vaccine technologies. This in-formation can then be used as a basis for evidence-based communication activities by regulators and public health bodies in an emergency context.
- 22 June 2023
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (8) , 2338-2340
European Medicines Agency seeks stakeholders' views on future transparency measures for clinical trials
- 22 June 2023
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (8) , 2338-2340
European Medicines Agency seeks stakeholders' views on future transparency measures for clinical trials